FDA 510(k) clearance would unlock the U.S. market for INBS's drug screening system, which is already generating revenue internationally. Monitor for FDA acceptance of the submission and any follow-up questions; a clearance decision typically takes 90-180 days. The stock may trade on binary regulatory news.
Price Chart
Executive Summary
Intelligent Bio Solutions announced it has submitted a 510(k) premarket notification to the FDA seeking clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The submission package includes clinical data showing >98% accuracy, >94% sensitivity, and 100% specificity from three U.S. sites. This is a non-financial regulatory milestone that opens a path to the multi-billion-dollar U.S. drug screening market, but FDA review timelines and clearance are uncertain.
Key Facts
- Submitted 510(k) premarket notification to FDA for Intelligent Fingerprinting Drug Screening System to detect codeine.
- Method Comparison Study demonstrated accuracy above 98%, sensitivity above 94%, and 100% specificity across three independent U.S. clinical sites.
- Submission package includes over 18,000 hours of data collection, 18 detailed test reports, and more than 170 attachments.
- System is already commercially deployed outside the U.S. in workplace, law enforcement, and government settings.
- U.S. drug screening market described as a multi-billion-dollar annual opportunity.
Financial Impact
No financial figures provided in the filing. The U.S. drug screening market is described as 'multi-billion-dollar annual opportunity' but no specific revenue projections or deal values are stated.
Risk Factors
- FDA may request additional data or reject the 510(k) submission, delaying or preventing U.S. market entry.
- Company has a $7M market cap and no disclosed revenue figures — financial sustainability is a concern regardless of regulatory progress.
- 510(k) clearance is for codeine only; expansion to other drug panels would require additional submissions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041901 |
| Exhibit: ex99-1.htm | 0001493152-26-041901 |
| Document: 0001493152-26-041901-index-headers.html | 0001493152-26-041901 |
| Document: 0001493152-26-041901-index.html | 0001493152-26-041901 |
| Document: 0001493152-26-041901.txt | 0001493152-26-041901 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.72 (+2.08%) |
Oct 13, 2026 14d ago | 8-K | $1.45 | awaiting T+20 | — | $1.72 (+18.62%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.72 (−0.58%) |
Sep 15, 2026 6w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.72 (−12.69%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.72 (−16.91%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.72 (−23.21%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.72 (+25.22%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.72 (−35.58%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.72 (+35.58%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.72 (−48.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers